MicroRNA-30d-5p—A Potential New Therapeutic Target for Prevention of Ischemic Cardiomyopathy after Myocardial Infarction
Elke Boxhammer,
Vera Paar,
Bernhard Wernly,
Attila Kiss,
Moritz Mirna,
Achim Aigner,
Eylem Acar,
Simon Watzinger,
Bruno K. Podesser,
Roland Zauner,
Verena Wally,
Michael Ablinger,
Matthias Hackl,
Uta C. Hoppe,
Michael Lichtenauer
Affiliations
Elke Boxhammer
Internal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
Vera Paar
Internal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
Bernhard Wernly
Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University, 5110 Oberndorf, Austria
Attila Kiss
Ludwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria
Moritz Mirna
Internal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
Achim Aigner
Rudolf Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig University, 04107 Leipzig, Germany
Eylem Acar
Ludwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria
Simon Watzinger
Ludwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria
Bruno K. Podesser
Ludwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria
Roland Zauner
Dermatology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
Verena Wally
Dermatology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
Michael Ablinger
Dermatology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
Matthias Hackl
TAmiRNA GmbH, Muthgasse 18, 1110 Vienna, Austria
Uta C. Hoppe
Internal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
Michael Lichtenauer
Internal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
(1) Background and Objective: MicroRNAs (miRs) are biomarkers for assessing the extent of cardiac remodeling after myocardial infarction (MI) and important predictors of clinical outcome in heart failure. Overexpression of miR-30d-5p appears to have a cardioprotective effect. The aim of the present study was to demonstrate whether miR-30d-5p could be used as a potential therapeutic target to improve post-MI adverse remodeling. (2) Methods and Results: MiR profiling was performed by next-generation sequencing to assess different expression patterns in ischemic vs. healthy myocardium in a rat model of MI. MiR-30d-5p was significantly downregulated (p p = 0.0172). To gain insight into infarct healing, scratch assays were used to obtain information on cell migration in human umbilical vein endothelial cells (HUVECs). Gap closure was significantly faster in the mimic-treated cells 20 h post-scratching (12.4% more than the scrambled control after 20 h; p = 0.013). To analyze the anti-apoptotic quality of miR-30d-5p, the ratio between phosphorylated p53 and total p53 was evaluated in human cardiomyocytes using ELISA. Under the influence of the miR-30d-5p mimic, cardiomyocytes demonstrated a decreased pp53/total p53 ratio (0.66 ± 0.08 vs. 0.81 ± 0.17), showing a distinct tendency (p = 0.055) to decrease the apoptosis rate compared to the control group. (3) Conclusion: Using a mimic of miR-30d-5p underlines the cardioprotective effect of miR-30d-5p in MI and could reduce the risk for development of ischemic cardiomyopathy.